ArticleFrontiers in cellular and infection microbiology2025
Partial normalization of microbiota dysbiosis in condyloma acuminatum patients following treatment.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Differential Signature of Gut Microbiota in Female Patients with Condyloma Acuminatum and Its Association with Persistent Human Papillomavirus Infection.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Condyloma acuminatum (CA) is the most common sexually transmitted disease and the presence of microbiota dysbiosis has been observed to promote the progress of the disease. However, the explicit characteristics of microbiota dysbiosis in CA patients have not been well elucidated yet. Methods: We recruited 40 CA patients who received QYXJ (an in-hospital prescription that has been used to treat CA for many years) treatment and 40 healthy controls (HC) in the current study. Before and after two weeks QYXJ administration, the skin microbiome of each patient was assessed using 16S rRNA gene sequencing. Results: Here, we found increased relative abundances of Conclusion: This study further confirmed the changes of skin microbiome in CA pathogenesis and firstly revealed the protective effects of QYXJ in microbiota dysbiosis resolution, suggesting its potential role as a novel method for CA treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.